SELECT id, `name`, primary_key, `key`, treemapgroup, name_cn, zacks_table_name, compare_key, compare_display_name from gurufocu_main.financial_definition where termpagedisplay=1 and `key` = 'IS_FeeRevenueAndOtherIncome' ValiRx (LSE:VAL) Fees and Other Income
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Fees and Other Income

ValiRx (LSE:VAL) Fees and Other Income


View and export this data going back to 2000. Start your Free Trial

Fees and Other Income only applies to insurance companies.

ValiRx (LSE:VAL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Fees and Other Income
Comparable Companies
LSE:OCTP AQSE:INC LSE:GENF LSE:IXI LSE:FAB LSE:BSFA LSE:APTA LSE:CIZ LSE:EVG LSE:RENE OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
EAJF:Germany
Address
4 Barling Way, Eliot Park Innovation Centre, Nuneaton, GBR, CV10 7RH
Website
https://www.valirx.com
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.